Background: Breast cancer resistance protein (BCRP), or ATP-binding cassette subfamily G member 2 (ABCG2), is an ATP-binding cassette (ABC) transporter that mediates energy-dependent transport of substrate drugs out of the cell. Its overexpression may contribute to intrinsic drug resistance in vitro. However, the current literature has not yet clarified the clinical significance of BCRP/ABCG2 in invasive breast carcinoma. Objectives: The purpose of this study was to validate the expression of BCRP/ABCG2 in invasive breast carcinoma and its role in response to neoadjuvant chemotherapy. Methods: In this study, a pretherapeutic core biopsy was performed in 222 patients. BCRP/ABCG2 expression in carcinoma tissue was measured by immunohistochemistry. BCRP/ABCG2 expression correlations with clinicopathological features, molecular subtypes, and therapy response after neoadjuvant chemotherapy were investigated. Results: The results showed that BCRP/ABCG2 was expressed in different molecular subtypes. The proportions of patients with high BCRP/ABCG2 expression were similar in luminal A and luminal B tumors (luminal B, 80%; luminal A, 78%), compared with other molecular subtypes (triple-negative, 63%; HER2+, 58%, p = 0.05). BCRP/ABCG2 expression and the number of lymphatic metastases (p = 0.001) and tumor size (p = 0.011) demonstrated a statistically significant correlation. Low BCRP/ABCG2 expression was associated with an increased pathological complete response (pCR) rate of 38%, higher than the 19% in tumors with high BCRP/ABCG2 expression (p = 0.002). In multivariable analysis, BCRP/ABCG2 and hormone receptor (HR) expression were identified as independent risk factors of pCR (p = 0.003 and p = 0.013, respectively). Conclusions: BCRP/ABCG2 is highly expressed in HR-positive breast cancer. High BCRP/ABCG2 expression is associated with lymphatic metastasis, tumor size, and poor pCR. BCRP/ABCG2 may be a novel potential biomarker that can predict clinical progression and therapy response after neoadjuvant chemotherapy.

1.
Gnant
M
,
Steger
GG
,
Bartsch
R
.
Pathological complete remission and long-term outcome-what do we know in 2016
.
Lancet Oncol
.
2016 Jun
;
17
(
6
):
693
4
. http://dx.doi.org/10.1016/S1470-2045(16)30038-9.
2.
Cortazar
P
,
Zhang
L
,
Untch
M
,
Mehta
K
,
Costantino
JP
,
Wolmark
N
,
.
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
.
Lancet
.
2014 Jul
;
384
(
9938
):
164
72
.
3.
Wang-Lopez
Q
,
Chalabi
N
,
Abrial
C
,
Radosevic-Robin
N
,
Durando
X
,
Mouret-Reynier
M-A
,
.
Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer
.
Crit Rev Oncol Hematol
.
2015 Jul
;
95
(
1
):
88
104
.
4.
Moulder
S
.
Intrinsic resistance to chemotherapy in breast cancer
.
Womens Health
.
2010 Nov
;
6
(
6
):
821
30
.
5.
Takara
K
,
Sakaeda
T
,
Okumura
K
.
An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy
.
Curr Pharm Des
.
2006
;
12
(
3
):
273
86
.
6.
Mehendale-Munj
S
,
Sawant
S
.
Breast cancer resistance protein: a potential therapeutic target for cancer
.
Curr Drug Targets
.
2021
;
22
(
4
):
420
8
.
7.
Maliepaard
M
,
Scheffer
GL
,
Faneyte
IF
,
van Gastelen
MA
,
Pijnenborg
AC
,
Schinkel
AH
.
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues
.
Cancer Res
.
2001 Apr
;
61
(
8
):
3458
64
.
8.
Xiang
L
,
Su
P
,
Xia
S
,
Liu
Z
,
Wang
Y
,
Gao
P
,
.
ABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma
.
Diagn Pathol
.
2011 Sep
;
6
:
90
.
9.
Ogston
KN
,
Miller
ID
,
Payne
S
,
Hutcheon
AW
,
Sarkar
TK
,
Smith
I
,
.
A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival
.
Breast
.
2003 Oct
;
12
(
5
):
320
7
.
10.
Vaidya
JS
,
Massarut
S
,
Vaidya
HJ
,
Alexander
EC
,
Richards
T
,
Caris
JA
,
.
Rethinking neoadjuvant chemotherapy for breast cancer
.
BMJ
.
2018 Jan
;
360
:
j5913
.
11.
Puig
CA
,
Hoskin
TL
,
Day
CN
,
Habermann
EB
,
Boughey
JC
.
National trends in the use of neoadjuvant chemotherapy for hormone receptor-negative breast cancer: a national cancer data base study
.
Ann Surg Oncol
.
2017 May
;
24
(
5
):
1242
50
.
12.
Knutsen
T
,
Rao
VK
,
Ried
T
,
Mickley
L
,
Schneider
E
,
Miyake
K
,
.
Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines
.
Gene Chro Can
.
2000 Jan
;
27
(
1
):
110
6
.
13.
Bailey-Dell
KJ
,
Hassel
B
,
Doyle
LA
,
Ross
DD
.
Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene
.
Biochim Biophys Acta
.
2001 Sep
;
1520
:
234
41
.
14.
Diestra
JE
,
Scheffer
GL
,
Catala
I
,
Maliepaard
M
,
Schellens
JH
,
Scheper
RJ
,
.
Frequent expression of the multi-drug resistance associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material
.
J Pathol
.
2002 Oct
;
198
(
2
):
213
9
.
15.
Jézéquel
P
,
Gouraud
W
,
Ben Azzouz
F
,
Guérin-Charbonnel
C
,
Juin
P
,
Lasla
H
,
.
bc-GenExMiner 4.5: new mining module computes breast cancer differential gene expression analyses
.
Database
.
2021
:
baab007
.
16.
Nedeljkovi
M
,
Tani
N
,
Prvanovi
M
,
Milovanovi
Z
,
Tani
N
.
Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer
.
Breast Cancer
.
2021 Jun
;
28
(
3
):
727
36
.
17.
Kanzaki
A
,
Toi
M
,
Nakayama
K
,
Bando
H
,
Mutoh
M
,
Uchida
T
,
.
Expression of multidrug resistance-related transporters in human breast carcinoma
.
Jpn J Cancer Res
.
2001Apr
;
92
(
4
):
452
8
.
18.
Omran
OM
.
The prognostic value of breast cancer resistance protein (BCRB/ABCG2) expression in breast carcinomas
.
J Environ Pathol Toxicol Oncol
.
2012
;
31
(
4
):
367
76
.
19.
Huo
Q
,
Yuan
J
,
Zhu
T
,
Li
Z
,
Xie
N
.
A combined bioinformatic and nanoparticle-based study reveal the role of abcg2 in the resistance of breast cancer
.
Recent Pat Anticancer Drug Discov
.
2021 Feb
;
18
:
393
.
20.
Maciejczyk
A
,
Szelachowska
J
,
Ekiert
M
,
Matkowski
R
,
Hałoń
A
,
Surowiak
P
.
Analysis of BCRP expression in breast cancer patients
.
Ginekol Pol
.
2012 Sep
;
83
(
9
):
681
7
.
21.
Horsey
AJ
,
Cox
MH
,
Sarwat
S
,
Kerr
ID
.
The multidrug transporter ABCG2: still more questions than answers
.
Biochem Soc Trans
.
2016 Jun
;
44
:
824
30
.
22.
Sicchieri
RD
,
da Silveira
WA
,
Mandarano
LR
,
de Oliveira
TM
,
Carrara
HH
,
Muglia
VF
,
.
ABCG2 is a potential marker of tumor-initiating cells in breast cancer
.
Tumour Biol
.
2015 Dec
;
36
(
12
):
9233
43
.
23.
Haimeur
A
,
Conseil
G
,
Deeley
RG
,
Cole
SP
.
The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation
.
Curr Drug Metab
.
2004 Feb
;
5
(
1
):
21
53
.
24.
Ghafouri
H
,
Ghaderi
B
,
Amini
S
,
Nikkhoo
B
,
Abdi
M
,
Hoseini
A
.
Association of ABCB1 and ABCG2 single nucleotide polymorphisms with clinical findings and response to chemotherapy treatments in Kurdish patients with breast cancer
.
Tumour Biol
.
2016 Jun
;
37
(
6
):
7901
6
.
25.
Diana
DE
,
Kim
B
,
Hanby
AM
,
Verghese
ET
,
Sims
AH
,
Hughes
TA
.
Neoadjuvant endocrine therapy in breast cancer upregulates the cytotoxic drug pump ABCG2/BCRP, and may lead to resistance to subsequent chemotherapy
.
Clin Breast Cancer
.
2018 Dec
;
18
(
6
):
481
8
.
You do not currently have access to this content.